Search

for
Search:

GlossaryGLP-1 receptor agonists

mimic a hormone to regulate blood sugar and promote fullness

GLP-1 receptor agonists are a class of medications that mimic the action of the glucagon-like peptide-1 (GLP-1) hormone, which helps regulate blood sugar levels by enhancing insulin secretion and inhibiting glucagon release. They are commonly used in the treatment of type 2 diabetes and can also promote weight loss by slowing gastric emptying and increasing feelings of fullness.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 231 results

Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

research Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

November 2024 in “Circulation”

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations, August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

research A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

61 citations, January 2015 in “Hormones”

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

research Cardiovascular Profile of Pharmacological Agents Used for the Management of Polycystic Ovary Syndrome

4 citations, January 2019 in “Therapeutic Advances in Endocrinology and Metabolism”

Medications for PCOS don't seem to raise heart disease risk.

research Current Possible Treatment Approaches of Polycystic Ovary Syndrome (PCOS)

February 2024 in “Journal of Education, Health and Sport”

Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.

View more "glucagon-like peptide-1 receptor agonists" in research →

Community Join

1 / 1 results

community Gyno & testoterone level

in Finasteride 282 upvotes 6 months ago

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.